Neuroendocrine differentiation (NED) in prostate cancer is a well-recognized phenotypic
change by which prostate cancer cells transdifferentiate into neuroendocrine-like (NE-like) …

Neuroendocrine differentiation (NED) secondary to androgen deprivation therapy (ADT)
may be frequent in various stages of prostate cancer (PC), particularly in castration-resistant …

Background Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of castration-
resistant prostate cancer that typically does not respond to androgen receptor pathway …

Neuroendocrine (NE) differentiation is a well-recognized phenotypic change of prostate
cancer after androgen deprivation therapy (ADT), and it ultimately develops into an …

Abstract Treatment of prostate cancer (PC a), a leading cause of cancer among males, lacks
successful strategies especially in advanced, hormone‐refractory stages. Some clinical …

The recently developed anti-androgen enzalutamide also known as (MDV3100) has the
advantage to prolong by 4.8 months the survival of castration resistant prostate cancer …

MicroRNAs (miRNAs) are small noncoding RNA molecules that post-transcriptionally
regulate gene expression. Dysregulation of miRNAs is frequently associated with disease …

AKT isoforms are expressed in prostate cancer and their expression and localization have
different associations with clinical characteristics. However, the distinct roles of the AKT …

Prostate cancer (PCa) remains the second-leading cause of cancer-related deaths in
American men with an estimated mortality of more than 26,000 in 2016 alone. Aggressive …

Resistance to the current Androgen Receptor Signaling Inhibitor (ARSI) therapies has led to
higher incidences of therapy-induced neuroendocrine-like prostate cancer (t-NEPC). This …